Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021

Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021




Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DTxCognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company developing a new category of therapeutic treatments for neurodegenerative diseases starting with Alzheimer’s Disease, today announced that Brent Vaughan, CEO, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 11:00-11:25 am ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About Cognito Therapeutics

Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders. Its non-invasive neuromodulation platform was based on technology developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead digital therapeutic reported positive Phase 2 results in Alzheimer’s Disease, and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

Contacts

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com